Our findings indicate that while a single dose of IL-15 complexes administered intratumorally is insufficient in producing a significant change to anti-PD-1 immunotherapy, a second dose generates an increase in anti-tumoral immune markers in murine EO771 breast cancer as well as increased survival. Here, IL15 is linked to breast cancer.